Presentation at EASD 2026 Symposium: Efficacy and Safety of Survodutide, a Novel Glucagon/GLP-1 Receptor Dual Agonist, for Treatment of People with Obesity and T2D: Primary Data from the SYNCHRONIZE®-2 Trial

The above is a presentation part of the "Glucagon receptor/GLP-1 receptor dual agonism in people with obesity and type 2 diabetes: insights from the SYNCHRONIZE Phase 3 studies of survodutide" Symposium at EASD 2026.

Authors

Publication Details

Journal
Boehringer Ingelheim
Published
2026-10-27
DOI
https://doi.org/10.60915/boehringer-figshare.34733865
Citations
5
Primary Topic
Diabetes Treatment and Management
Type
article
Field-Weighted Citation Impact
25.20
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Presentation at EASD 2026 Symposium: Efficacy and Safety of Survodutide, a Novel Glucagon/GLP-1 Receptor Dual Agonist, for Treatment of People with Obesity and T2D: Primary Data from the SYNCHRONIZE®-2 Trial

Sean Wharton
5 citations
Boehringer Ingelheim
Diabetes Treatment and Management
25.20
article

Presentation at EASD 2026 Symposium: Efficacy and Safety of Survodutide, a Novel Glucagon/GLP-1 Receptor Dual Agonist, for Treatment of People with Obesity and T2D: Primary Data from the SYNCHRONIZE®-2 Trial

Sean Wharton
article en
5 citations

Abstract

The above is a presentation part of the "Glucagon receptor/GLP-1 receptor dual agonism in people with obesity and type 2 diabetes: insights from the SYNCHRONIZE Phase 3 studies of survodutide" Symposium at EASD 2026.

Boehringer Ingelheim
Good health and well-being
Openalex Percentile: Top 0%
Diabetes Treatment and Management
25.20
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon
Presentation at EASD 2026 Symposium: Efficacy and Safety of Survodutide, a Novel Glucagon/GLP-1 Receptor Dual Agonist, for Treatment of People with Obesity and T2D: Primary Data from the SYNCHRONIZE®-2 Trial — Sean Wharton · Boehringer Ingelheim (2026) | TGRS Research Map | TGRS